- Researchers investigated if intravenous tirofiban improves outcomes for stroke patients who respond poorly to tenecteplase without large vessel occlusions.
- This randomized, double-blind trial enrolled 359 patients across 37 hospitals who showed insufficient clinical improvement after receiving intravenous tenecteplase.
- Excellent outcomes occurred in 63.8 percent of the tirofiban group versus 52.2 percent for placebo (risk ratio 1.22; P = .03).
- The researchers concluded that adjunctive tirofiban significantly increases the likelihood of achieving a modified Rankin Scale score of 0 or 1.
- These findings suggest tirofiban is a viable rescue therapy for patients failing to stabilize after initial thrombolysis with tenecteplase.
Stabilizing the Post-Thrombolysis Ischemic Penumbra
Intravenous thrombolysis is a cornerstone of reperfusion therapy for acute ischemic stroke, yet many patients do not achieve functional independence, often due to incomplete recanalization or early re-occlusion [1, 2]. While thrombolytic agents dissolve fibrin, they do not inhibit the platelet aggregation that can contribute to microvascular obstruction, a phenomenon known as "no-reflow", which impairs tissue perfusion even after the primary artery is opened [3, 4]. For patients who show an inadequate clinical response to initial thrombolysis, particularly those without a large vessel occlusion amenable to mechanical thrombectomy, current guidelines offer few pharmacological options [5, 6]. Glycoprotein IIb/IIIa inhibitors, a class of potent intravenous antiplatelet agents that block the final common pathway of platelet aggregation, have been investigated to stabilize vessel patency, but concerns over symptomatic intracranial hemorrhage have historically limited their use in the immediate post-thrombolysis period [7, 8]. A recent randomized controlled trial provides new data on the efficacy and safety of this adjunctive strategy in a carefully selected patient population.
Targeting the Non-Large Vessel Population
To address this clinical gap, an investigator-initiated, randomized, double-blind, placebo-controlled trial was conducted across 37 hospitals in China. The study was designed to evaluate adjunctive tirofiban in a specific and frequently encountered cohort: 359 patients with acute ischemic stroke who lacked a large or medium vessel occlusion or a cardioembolic source. This focus on strokes likely driven by small vessel disease or in situ thrombosis isolates a population for whom endovascular thrombectomy is not an option, making medical management paramount. Recruitment took place between April 24, 2024, and July 16, 2025, with final follow-up on October 11, 2025.
A key entry criterion was an inadequate clinical response to initial intravenous tenecteplase, a common and challenging scenario in stroke care. The investigators defined this as a lack of significant improvement, neurological deterioration, or clinical fluctuation based on serial assessments with the National Institutes of Health Stroke Scale (a standardized tool for quantifying neurological deficits) within 4 to 24 hours of thrombolysis. By targeting this specific post-thrombolysis window, the trial directly addresses the critical period when a patient’s trajectory is uncertain and decisions about escalating therapy must be made.
The study population had a mean age of 66 years, with 141 females (39.3%). The trial demonstrated robust execution, as 358 of 359 patients (99.7%) completed the 90-day follow-up. This high completion rate strengthens the validity of the findings and ensures the outcome data accurately reflect the effects of the intervention on the randomized cohort.
Tirofiban Dosing and Antiplatelet Transition
The intervention protocol was designed to provide potent but temporary antiplatelet effect during the period of highest risk for re-occlusion. In the treatment arm, 177 patients received intravenous tirofiban, a glycoprotein IIb/IIIa inhibitor. The regimen began with a 0.3-μg/kg/min loading bolus over 30 minutes, followed by a continuous maintenance infusion of 0.075 μg/kg/min for up to 47.5 hours. The 182 patients in the control group received a matching placebo infusion. Both interventions were initiated between 4 and 24 hours after tenecteplase administration, coinciding with the identification of an inadequate clinical response.
To ensure a safe transition to long-term secondary prevention, the researchers implemented a staggered oral antiplatelet strategy. In the placebo group, standard oral therapy with aspirin and/or clopidogrel was started 24 hours after thrombolysis. In the tirofiban group, this transition was delayed until 44 hours post-thrombolysis. This carefully timed delay was intended to minimize the period of overlapping antiplatelet mechanisms, thereby reducing the potential for bleeding complications as the potent intravenous agent was discontinued. Following this initial period, all patients continued their prescribed oral antiplatelet regimen through the 90-day follow-up.
Functional Independence and Safety Profile
The trial's primary efficacy outcome was the proportion of patients achieving an excellent functional outcome, defined as a score of 0 (no symptoms) or 1 (no significant disability) on the modified Rankin Scale at 90 days. The findings demonstrated a significant benefit for the intervention. An excellent outcome was achieved by 113 patients (63.8%) in the tirofiban group compared to 95 patients (52.2%) in the placebo group. This corresponds to a risk ratio of 1.22 (95% CI, 1.02-1.46; P = .03), indicating that patients receiving tirofiban were 22% more likely to have little to no disability at three months.
The safety analysis focused on the most feared complication of aggressive antiplatelet therapy after thrombolysis. Symptomatic intracranial hemorrhage within 48 hours occurred in one patient (0.9%) in the tirofiban group and in no patients in the placebo group. All-cause mortality at 90 days was low in both arms, with one death (0.6%) in the tirofiban group and three deaths (1.6%) in the placebo group. These results suggest that for patients with acute ischemic stroke without large vessel occlusion who respond poorly to tenecteplase, adjunctive intravenous tirofiban improves the likelihood of an excellent functional outcome with a low incidence of severe hemorrhagic complications.
References
1. Spina E, Spiezia AL, Pia FD, et al. Efficacy and safety of early intravenous administration of tirofiban after thrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.. Journal of thrombosis and thrombolysis. 2026. doi:10.1007/s11239-026-03273-9
2. Gadelmawla A, Emara A, Diaa A, et al. Abstract A007: Adjunct Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke: A Systemic Review and Meta-analysis of Randomized Trials. Stroke. 2026. doi:10.1161/str.57.suppl_1.a007
3. Gadelmawla AF, Emara A, El-Farargy SH, et al. Adjunct tirofiban after intravenous thrombolysis in acute ischemic stroke: a GRADE-guided meta-analysis of randomized trials with trial sequential analysis.. Journal of thrombosis and thrombolysis. 2025. doi:10.1007/s11239-025-03213-z
4. Menegat BLRS, Menegat ALRS, Dantas CR, et al. Abstract TP10: Effects of Tirofiban on Early Neurological Deterioration in Patients With Acute Ischemic Stroke: A Systematic Review and Meta- Analysis. Stroke. 2025. doi:10.1161/str.56.suppl_1.tp10
5. Monteiro GDA, Mutarelli A, Leite M, et al. Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials.. Clinical neurology and neurosurgery. 2024. doi:10.1016/j.clineuro.2024.108602
6. Jiao J, Zhang J, Lan X, Guo J, Wang S. Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis. Frontiers in Neurology. 2026. doi:10.3389/fneur.2026.1823316
7. Ayyan M, Ahmad A, Fuadah S, et al. Abstract 4147434: Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Circulation. 2024. doi:10.1161/circ.150.suppl_1.4147434
8. Monteiro GDA, Leite M, Gonçalves OR, et al. Efficacy and safety of intravenous tirofiban combined with reperfusion therapy versus reperfusion therapy alone in acute ischemic stroke: a meta-analysis of randomized controlled trials.. Journal of thrombosis and thrombolysis. 2025. doi:10.1007/s11239-025-03094-2